TITLE: Disease Heterogeneity and Immune Biomarkers in Preclinical Mouse Models of Ovarian Carcinogenesis

PRINCIPAL INVESTIGATOR: Dr. Anda Vlad, M.D., Ph.D.

CONTRACTING ORGANIZATION: Magee-Womens Hospital
Pittsburgh, PA 15213

REPORT DATE: August 2014

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
**Disease Heterogeneity and Immune Biomarkers in Preclinical Mouse Models of Ovarian Carcinogenesis**

**Dr. Anda M. Vlad**

E-Mail: vladam@upmc.edu

**7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)**

Magee-Womens Hospital
Pittsburgh, PA 15213

**9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)**

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

**12. DISTRIBUTION / AVAILABILITY STATEMENT**

Approved for Public Release; Distribution Unlimited

**14. ABSTRACT**

Human studies performed in years 3 and 4 led to the discovery of several immune genes that are differentially expressed in endometriosis, atypical endometriosis, endometriosis-associated ovarian cancer (EAOc, endometrial and clear cell). Of these genes, complement pathway genes were consistently present, suggesting that complement-induced immunity may be involved in the pathogenic events during the transition from endometriosis to EAOc.

In year 4, we have focused on immune gene signatures associated with response to immune therapy. Using our new transplantable ovarian cancer model in completely syngeneic immune competent mice, we tested in vivo the efficacy of anti-PDL1 antibody administered intraperitoneal (IP). PD-L1 is a molecule in the immune checkpoint pathway. It binds to PD-1 receptor on T cells and induces inhibition of effector function of cytolytic T cells. Our results demonstrate that blocking the PD-1/PD-L1 interaction through IP administration of anti-PD-L1 antibody significantly increases survival and triggers upregulation of several immune genes associated with CD8 T cell function. Immune checkpoint blockade has been proven effective in recent clinical trials mostly in melanoma, lung and renal carcinomas. Our results provide strong support in its suitability in ovarian cancer.

**15. SUBJECT TERMS**

Ovarian cancer, preclinical animal model, MUC1, immune therapy
<table>
<thead>
<tr>
<th>16. SECURITY CLASSIFICATION OF:</th>
<th>17. LIMITATION OF ABSTRACT</th>
<th>18. NUMBER OF PAGES</th>
<th>19a. NAME OF RESPONSIBLE PERSON</th>
<th>19b. TELEPHONE NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. REPORT U</td>
<td>b. ABSTRACT U</td>
<td>c. THIS PAGE U</td>
<td>U</td>
<td>USAMRMC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>U</td>
<td>(include area code)</td>
</tr>
</tbody>
</table>
Table of Contents

Introduction ...................................................................................................................... 5

Body ............................................................................................................................... 5

Key Research Accomplishments .................................................................................. 6

Reportable Outcomes ................................................................................................. 7

Conclusion .................................................................................................................... 8

References .................................................................................................................. 8

Supporting data ........................................................................................................... 9

Appendices .................................................................................................................. 11
INTRODUCTION
Our work combines studies on ovarian cancer disease pathogenesis and immune biology, musing a combination of human clinical samples and novel in vivo preclinical models. The preclinical mouse model used here employs the previously described, genetically engineered mice (Cre-loxP) that carry the lox-Stop-loxP-KrasG12D oncoallele and a floxed region within region encoding for the phosphatase domain of the Pten gene (KrasPten mice). We postulate that similarly to intrabursal injections, AdCre injection along various other sites of the genital tract of KrasPten and of our recently described MUC1KrasPten mice will allow us to study in vivo tumor initiation and progression and to identify important disease pathogenesis mechanisms in ovarian tumors and other cancers of the genital tract. Furthermore, in conjunction with our clinical studies we aim to identify novel disease biomarkers that may help in the early diagnostic of ovarian cancer and provide new therapeutic/preventive targets.

BODY
We present below our progress in year 4, according to the tasks and milestones described in the original application.
**Aim 1 (Months 1-18).** To investigate the Müllerian tract versus the OSE as the potential originating sites for ovarian epithelial tumors in KrasPten mice.

All aim 1 tasks have been completed, and milestone #1 (publication) achieved. Our manuscript describes the morphopathogenic characteristics of lesions triggered by AdCre injections via intrabursal, intraductal and intrauterine routes and the immune suppressive environment at each location. (ref.6; Tirodkar, Budiu et al, 2014 Jul 31;9(7):e102409.PMID 25078979, PDF attached). Furthermore, we show that survival for oviduct tumors was significantly lower than for endometrial tumors ($p=0.0015$), yet similar to survival for ovarian cancer. Oviducts seem to favor the development of high grade tumors, providing preclinical evidence in support of the postulated role of fallopian tubes as the originating site for high grade human ovarian tumors.

**Aim 2:** To profile disease heterogeneity and to identify immune biomarkers of natural and vaccine-induced immune responses in mice with either endometriosis, ovarian cancer or endometriosis progressing to ovarian cancer.

This aim has been largely completed. Using a novel transplantable ovarian cancer tumor model based on 2F8 cell line, we recently tested in vivo efficacy of a PD-L1 blockade. 2F8 cells were derived from a primary ovarian tumor in MKPOSE mice we previously described (2). Although PDL1 expression is low in 2F8 cells at baseline in vitro, there is PDL1 upregulation in vivo as demonstrated by ascites isolated cells (Fig. 1). The therapeutic PD-L1 blockade employed three administrations of anti-PDL1 (200ug/dose/mouse)) administered IP two weeks apart. Treatment was started 21 days after tumor induction, and administered intraperitoneal (IP) every two weeks for a total of 3 doses, according to the schema in Fig.2. Kaplan Meyer curves show that IP administration of anti-PD-L1 significantly increases survival (Fig. 2). These findings are encouraging, given (1) treatment initiation at late stage, (2) low dose/low frequency administration and (3) low PD-L1 expression on tumors.

Furthermore, heatmap analyses demonstrate clear separation between responder and non-responder mice (Fig. 3). Of the 82 differentially expressed (DE) immune genes, several of the immune genes upregulated in the spleens of responder mice correspond to the CD3, CD8 T cells.

In line with these gene expression analyses, our protein measurements via flow cytometry clearly demonstrate a systemic immune response associated with significantly increased CD3, CD4 and CD8 T cell accumulation in the spleens of responding mice (Fig 4). In addition, the tumors of responding mice (although much smaller in size than those in the control treated group were highly infiltrated by T cells (Fig. 5), as detected by IHC.

The findings have been incorporated in a manuscript that will be soon submitted for publication.
Current studies focus on understanding Th1/Th2 balance in the host at the time of treatment initiation with PD-1/PD-L1 blockers as potential predictors of response and/or for patient selection for adjusted protocols.

**Aim 3:** To validate in human specimens the disease biomarkers identified (in aim 2) in mice with endometriosis and ovarian tumors.

We have completed this aim.

Our studies used a cohort of 120 paraffin tissue blocks comprising of normal endometrium (n=32), benign endometriosis (n=30), atypical endometriosis (n=15) and EAOC (n=43). Serous tumors (n=15) were included as non-endometriosis associated controls. The immune microenvironment was profiled using Nanostring and the nCounter® GX Human Immunology Kit, comprising probes for a total of 511 immune genes.

One third of the endometriosis patients revealed a tumor-like inflammation profile, suggesting that cancer-like immune signatures may develop earlier, in patients classified as clinically benign. Gene expression analyses revealed the complement pathway as most prominently involved in both endometriosis and EAOC.

Complement proteins are abundantly present in epithelial cells in both benign and malignant lesions. Mechanistic studies in ovarian surface epithelial (OSE) cells from mice with conditional (Cre-loxP) mutations show intrinsic production of complement in epithelia and demonstrate an early link between Kras- and Pten-driven pathways and complement upregulation. Downregulation of complement in these cells interferes with cell proliferation. These findings reveal new characteristics of inflammation in precursor lesions and point to previously unknown roles of complement in endometriosis and EAOC.

The manuscript detailing this work has been well reviewed at Clinical Cancer Research. Requested revisions have been addressed and final decision on the revised manuscript is currently pending.

**Progress on Milestone #1:** first round of publication submissions. This milestone has been completed (1, 2).

**Progress on Milestone # 2:** second round of publication submissions. This milestone has been completed (references 3, 4 and 6)

**Progress on Milestone # 3:** first R01 submission. Originally planned for year 3, we report that we secured our first R01 earlier than proposed, in year 2.

Based on the encouraging in vivo results from our preclinical studies using anti-PDL1, we recently applied for and received funding for a one year developmental research project (DRP), part of the University of Pittsburgh Cancer Institute/ Roswell Park Cancer Institute (UPCI/RPCI) Ovarian Cancer SPORE.

**KEY RESEARCH ACCOMPLISHMENTS**

- Human studies of immune profiling via Nanostring revealed that chronic inflammation associated with progression to premalignancy (defined here as cellular atypia, no overt cancer yet present) triggers complement upregulation. These are the first studies to show the role of complement in endometriosis and to demonstrate that chronic benign endometriosis-lesions may harbor a tumor-like immune gene signature before tumors occur.
- Preclinical mouse studies with PD-L1 demonstrate in vivo anti-tumor efficacy and reveal an immune gene expression signature that correlates with survival. The efficacy of this approach and the potential translational impact it carries is further enhanced by the fact that (i) efficacy occurs even when treatment is started late; (ii) PD-L1 expression of the tumor is low.
- Preclinical results with PD-L1 blockade created a basis for a new grant submission and for an Investigator Initiated Trial proposal submitted to Merck (PI-Marilyn Huang, MD; Co-I- Robert P Edwards, MD).
REPORTABLE OUTCOMES

- **Manuscripts** - published during the past 12 months


- **Abstracts** - We have submitted during the past year four abstracts:


- **Presentations** - Invited oral presentations

- **Animal models** - In years 1 and 2 we developed in vivo orthotopic tumor models for ovarian tumors, endometrial tumors (preceded by endometrial hyperplasia), ductal tumors and primary peritoneal carcinomatosis (in both female and male mice). During year 3 we developed a novel transplantable ovarian tumor model using a novel cell line (clone 2F8, Fig. 7). Expression of PD-L1 makes this cell line makes highly suitable for preclinical testing of PD-1/PD-L1 blockers.

- **Funding applied for based on work supported by this award.**

Funded applications:

1. Title: “Inflammation and Intratumoral Immune Checkpoint Activity in Ovarian Cancer
Type of award: Developmental Research Project (DRP), part of the University of Pittsburgh Cancer Institute/Roswell Park Cancer Institute (UPCI/RPCI) Ovarian Cancer SPORE
Role: Local PI
Period: May 2014- May 2015

2. Title: Immune Therapy Targeting Regulatory T cells Expressing Tim-3 and PD-1
Type of award: Developmental Research Project (DRP), part of the University of Pittsburgh Cancer Institute/Roswell Park Cancer Institute (UPCI/RPCI) Ovarian Cancer SPORE
Role: Local Co-I
Period: September 2014- September 2015
Not funded application
1. OCRF- Program Project Application (PIs: Vlad, Edwards, Huang)
2. DOD OCRP- Pilot Award (Role: Co-I; M Gach, PhD- PI)

Pending applications
1. NIH/NCI- R21 (Role: Co-I, 5% effort) – Xin Huang, PhD- PI
2. Sandy Rollman Ovarian Cancer Post-doctoral Award (Role: Mentor- Shannon Grabosch, MD-PI)

• Awards
1. Training faculty, T32 Award “Translational Research Training in Cancer Etiology and Prevention”- Cancer Institute of the National Institutes of Health, Award Number T32CA186873 (PI- Jian Min Yuan, PhD).


• Other

Named member of the Graduate Faculty, University of Pittsburgh, Pittsburgh PA (January, 2012)

CONCLUSION
Immune checkpoint blockade using anti-PD-L1 antibody shows in vivo efficacy, due increase in CD8 systemic T cells and increased T cell infiltration at the tumor site.
The effects

REFERENCES

SUPPORTING DATA

Fig. 1

2F8 tumor cells at baseline  2F8 tumor cells from ascites

Fig. 1. PD-L1 expression on 2F8 tumor cells via flow cytometry. The 2F8 cells express low levels of PD-L1 at baseline(left) but an in vivo upregulation is identified in 2F8 cells collected from ascites (right). PDL1 is also expressed at high levels on 2F8 tumor cells, as detected by IHC (right panel, brown staining).

Fig. 2

A

B

Fig. 2. Treatment schema and survival comparison of PD-L1 treated MUC1 transgenic mice with 2F8 ovarian cancer tumors. A. Treatment protocol and comparison of mice treated with 200 µg of either anti PD-L1 (n=6) or control Rat IgG antibody (n=6). All 12 mice received IP injections of 0.8 million MKP3004-2F8 cells at 8 weeks of age and began treatment 3 weeks after tumor induction. B. Kaplan Meyer survival curve showing
increase in survival in response to PD-L1 blockade (n=6, blue line) versus control antibody treated mice (n=6, red dotted line).  \( P=0.0012 \)

Fig. 3

![Heatmap analysis of DE genes (n=82.) that show clear separation of mice responding to PD-L1 (blue bar, n=6) versus controls (red bar, n=5). Many of the genes upregulated in responder mice (CD8, CD3e, CD3d belong to CD8 and CD3/TCR complex, suggesting a CD8 T cell mediated response.](image)

Fig. 4

![Phenotypic analysis of splenocytes, using flow cytometry. In line with the Nanostring findings, we found significant increases in CD3 (left panel) and CD4 (middle panel) and CD8 T cells (right panel) among splenocytes from responder mice, via flow cytometry. * p<0.05, Non-parametric students t test.](image)
Fig. 5. Immunohistochemistry (IHC) staining for tumor-infiltrating CD3 in six different mice, either PD-L1 (left column) or control-antibody treated (right column). Although some of the PD-L1 treated mice developed ovarian tumors, very low tumor burden was identified at necropsy. Furthermore, significant T cell infiltration was observed in tumors from PD-L1 treated mice vs. controls. IHC staining was performed to detect CD3z, according to manufacturer's protocol.

APPENDICES
MUC1 Positive, Kras and Pten Driven Mouse Gynecologic Tumors Replicate Human Tumors and Vary in Survival and Nuclear Grade Based on Anatomical Location

Tejas S. Tirodkar1,2, Raluca A. Budiu1,2,3, Esther Elishaev1,2, Lixin Zhang1,2, Jyothi T. Mony1,2, Joan Brozick2, Robert P. Edwards1,2,4, Anda M. Vlad1,2

1 Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America, 2 Magee Women’s Research Institute, Pittsburgh, Pennsylvania, United States of America, 3 Department of Pathology, Magee-Women’s Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America, 4 Magee-Women’s Hospital of the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America

Abstract

Activating mutations of Kras oncogene and deletions of Pten tumor suppressor gene play important roles in cancers of the female genital tract. We developed here new preclinical models for gynecologic cancers, using conditional (Cre-loxP) mice with floxed genetic alterations in Kras and Pten. The triple transgenic mice, briefly called MUC1KrasPten, express human MUC1 antigen as self and carry a silent oncogenic KrasG12D and Pten deletion mutation. Injection of Cre-encoding adenovirus (AdCre) in the ovarian bursa, oviduct or uterus activates the floxed mutations and initiates ovarian, oviductal, and endometrial cancer, respectively. Anatomical site-specific Cre-loxP recombination throughout the genital tract of MUC1KrasPten mice leads to MUC1 positive genital tract tumors, and the development of these tumors is influenced by the anatomical environment. Endometrioid histology was consistently displayed in all tumors of the murine genital tract (ovaries, oviducts, and uterus). Tumors showed increased expression of MUC1 glycoprotein and triggered de novo antibodies in tumor bearing hosts, mimicking the immunobiology seen in patients. In contrast to the ovarian and endometrial tumors, oviductal tumors showed higher nuclear grade. Survival for oviduct tumors was significantly lower than for endometrial tumors (p = 0.0015), yet similar to survival for ovarian cancer. Oviducts seem to favor the development of high grade tumors, providing preclinical evidence in support of the postulated role of fallopian tubes as the originating site for high grade human ovarian tumors.

Introduction

The American Cancer Society estimates over 91,000 new cases and 28,000 deaths due to gynecological cancers in 2013 [1]. Taken together, ovarian and endometrial tumors constitute about 78% of all female genital tract tumors. The most common gynecologic malignancy is endometrial cancer, which is often detected early and can be successfully treated with surgery and/or radiotherapy. In contrast, epithelial cancer of the ovary is relatively uncommon yet highly aggressive, accounting for most of the mortality. Primary fallopian tube cancers (without ovarian involvement) are also rare, accounting for 0.2% of cancer cases diagnosed annually [2] and, like ovarian tumors, are detected late and have a poor prognosis [3].

Traditionally, epithelial ovarian tumors have been thought to develop from the ovarian surface epithelium into four major histotypes: serous, endometrioid, mucinous and clear cell. It is now apparent that ovarian tumors are highly heterogeneous and may represent several different clinical entities, with distinct clinical precursors. High grade serous tumors carry p53 mutations and are considered to arise mostly in the fallopian tubes [4,5]. Although this type of tumor has been fully characterized through The Cancer Genome Atlas (TCGA) [6], similarly comprehensive analyses of the other ovarian cancer subtypes are not yet available [7–9]. Nevertheless, based on substantial evidence from several studies, it is currently accepted that, at least in part, the endometrioid and clear cell ovarian tumor histotypes share endometriosis as a putative common precursor [10] and display frequent inactivating mutations in ARID1A [7,11].

Low grade (type I) endometrial and ovarian cancers, as well as tubal intraepithelial carcinomas are frequently associated with oncogenic KRASG12D and PTEN deletion mutations [3,12] or altered expression [13]. The recent TCGA study of 373 endometrial tumors identified the KRAS and PTEN genes as...
being mutated in 24.6% and 77% of endometrioid tumors respectively, emphasizing the influence of these mutations in gynecologic cancer pathogenesis [14].

Involvement of the KRAS and PTEN pathways has led to the development of several genetically modified preclinical models for type I gynecological cancers [15–20]. Using conditionally transgenic mice carrying both oncogenic KRasG12D and a floxed Pten deletion, Dimulescu et al demonstrated the importance of these two pathways in triggering ovarian tumors with endometrioid histology [21]. Mice defective in Pten have also been reported as valuable preclinical models for endometrioid endometrial tumors [22]. However, in vivo modeling of oviduct tumors (the murine equivalent of fallopian tube tumors) has proven more challenging with only few orthotopic models reported to date [15,23].

While some of the mouse models for gynecologic malignancies have been helpful in delineating mechanisms of pathogenesis [21,24,25], they offer limited utility for immunotherapy due to the absence of well characterized mouse tumor antigens. To overcome this, we generated triple transgenic MUC1+/-/loxP-STOP-loxP-KrasG12D/+Pten+/-/loxP (or briefly MUC1/Kras/Pten) mice that, at steady state, express physiologic levels of human mucin 1 (MUC1) as self-antigen [26]. MUC1 is a membrane-bound glycoprotein that is overexpressed and aberrantly glycosylated in most epithelial cell-derived cancers, including genital tract tumors [27]. MUC1-targeted immunotherapy is under development for several cancers and has been administered so far to about 1200 patients, while more than 2000 patients are currently enrolled in ongoing clinical trials [28]. Using the MUC1/Kras/Pten mouse model, we have recently demonstrated that intrabursal injections of AdCre (to activate oncogenic Kras and induce Pten loss in the ovaries) [21,26] trigger endometrioid ovarian tumors. The tumors overexpress human MUC1 similarly to the human disease and respond to MUC1 immunotherapy, further strengthening the evidence on its efficacy as a target in ovarian cancer [26].

Here, we show how conditional mutations in Kras and Pten genes can be manipulated throughout the genital tract of double (Kras/Pten) and triple transgenic (MUC1/Kras/Pten) mice, using injections of Cre-encoding adenosivirus (AdCre) in the ovarian bursa, oviduct or uterine horns. Although all tumors, regardless of the originating site, display endometrioid histology, oviducts seem to favor the development of high grade tumors, providing preclinical evidence in support of the postulated role of fallopian tubes as the originating site for high grade, human ovarian tumors.

Materials and Methods
Survival surgery and administration of recombinant adenosivirus for tumor induction

All animal experiments were performed according to the protocol approved by the University of Pittsburgh Institutional Animal Care and Use Committee. Figure 1 shows the gross anatomy of the murine female genital tract from a healthy mouse, as well as a diagram of the ovarian bursa, oviduct and uterine sites of AdCre injection approach. Briefly, 7–10 weeks old female mice were synchronized by intra-peritoneal (IP) injection of 5 U of pregnant mare serum gonadotropin (PMSG, Sigma, St. Louis, MO), followed 48 hours later by 5 U of human chorionic gonadotropin (hCG, Calbiochem, Billerica, MA) as previously described [21]. Thirty six hours later, 5 μL of 2.5×10^7 plaque-forming units of Ad5CMVCre (University of Iowa Gene Transfer Vector Core) were delivered into either the ovarian bursa of the left ovary (n = 12), or the left oviduct (n = 9) or the left uterine horn (n = 12). The contra lateral (right) ovary/oviduct/uterine horn was used as control. A subset of oviduct injections (n = 4) were performed after clipping the oviduct at the proximal and distal ends using the GEM MicroClips (Synovis Life Technologies, Birmingham, AL) to ensure retention of the adenovirus within the oviduct.

The mice were sacrificed when the tumor mass on the injected side and/or ascites accumulation became visible or the mice showed signs of distress that were pre-defined as endpoints (i.e. hunched appearance, ruffled fur, difficulty in reaching for food or water etc).

Administration of AdLacZ adenosivirus and staining for LacZ expression

Ovulation was synchronized as above in control female mice. Five microliters of 2.5×10^7 plaque-forming units of the AdLacZ adenosivirus (University of Iowa Gene Transfer Vector Core) were then delivered into proximally and distally clipped oviducts (n = 2) or the uterus (n = 2). Mice were sacrificed 3–7 days post virus administration and the tissues fixed and stained for LacZ expression using the LacZ Detection Kit for Tissues, according to the manufacturer’s instructions (Invitrogen, San Diego, CA). After staining, the tissues were embedded in paraffin and blocks were sectioned at 5 μm, followed by H&E staining to visualize the histology of the AdLacZ infected sites.

Tissue isolation, histopathology and immunohistochemistry

Mouse internal organs (reproductive tract, spleen, peritoneal tumor masses and diaphragm), blood and ascites were collected during necropsy. Harvested tissue was fixed in 10% buffered formalin (Fisher Scientific, Kalamazoo, MI) for 24 hours, stored in 70% ethanol for 3 days and subsequently embedded in paraffin. Five micron sections were cut and the gross histopathology was assessed by H&E staining. For immunohistochemistry (IHC), the slides were blocked using 3% hydrogen peroxide in methanol and antigen retrieval was performed by boiling the slides for 20 minutes in citrate buffer, pH 6. The following antibodies were used for IHC: anti-human MUC-1 (HMPV, 1:50, Assay Biotech, Sunnyvale, CA), and desmin (sc7559, 1:50, Santa Cruz Biotechnology, Dallas, TX). Secondary antibodies used include anti-rabbit-HRP (K4003, Dako, Carpinteria, CA) for cytokerin 8, and anti-goat-HRP for desmin (sc2040, 1:50, Santa Cruz Biotechnology, Dallas, TX). Biotinylated anti-mouse IgG (550337, 1:100; BD Pharmingen, San Jose, CA) was used as the secondary antibody for anti-MUC1, followed by the VectaStain ABC Kit (Vector Laboratories, Burlingame, CA). The positive signal was detected using the DAB chromogen (DAB Substrate Kit, Abcam, Cambridge, MA) and the slides were counterstained using hematoxylin. To ensure specificity of staining, control sections were stained with either isotype control antibodies or no primary antibody.

Human serous tubal intraepithelial carcinoma (n = 1), human endometrioid endometrial carcinoma (n = 4) and human endometrial hyperplasia (n = 3) were obtained as per IRB guidelines from the Health Science Tissue Bank of the Magee Women’s Hospital, Pittsburgh. The protocols for processing and IHC staining of human tumors were similar to those described above, for mouse tumors.

Image processing and analysis

Images were acquired with the Nikon Eclipse 90i microscope and Nikon DS-Ri1 CCD camera, using NIS Elements AR software or the Nikon Eclipse 600 microscope with the DS-L3...
DNA isolation and PCR analysis of Cre-mediated recombination

DNA was isolated from 5 μm tissue sections of primary tumors using All Prep RNA/DNA/Protein isolation kit as per the manufacturer’s instructions (Qiagen, Valencia, CA). Tails from non-tumor bearing, healthy control mice were snap-frozen after collection and DNA was later isolated using Puregene DNA purification system (Gentra Systems, Minneapolis, MN), according to manufacturer’s instructions. The primers and complete PCR protocols to detect K-ras<sup>G12D</sup> and Pten deletion mutations have been described previously [26].

Flow cytometry

Spleens were collected at necropsy and a single cell suspension was obtained by passing the tissue fragments through a 70 μm cell strainer (BD Falcon, Franklin Lake, NJ, USA). Cells were stained with fluorescent antibodies for CD3 (PerCP), CD4 (Pacific Blue), and CD8 (APC-Cy7) (all antibodies from BD Biosciences, San Jose, CA), followed by intracellular staining for Foxp3 (eBioscience, San Diego, CA), according to the manufacturers’ protocols.

To detect anti-MUC1 antibodies, samples were incubated with IG10-MUC1 cells [29] expressing extracellular human MUC1. To detect bound antibodies, the cells were then stained with fluorescein tagged anti-mouse IgG and positive cells analyzed with LSRII (BD Biosciences) and processed in FACSDiva (BD Biosciences). Gates for positive cells were set using control ascites, from tumor bearing KrasPten (i.e. human MUC1 negative) mice.

ELISA

To detect MUC1-specific antibodies in sera from MUC1K-rasPten mice with tumors (n = 5 ovarian, n = 4 oviductal and n = 4 uterine tumors) we performed ELISA, as previously described by us and others [29]. Briefly, ELISA plates were coated with 10 μg/
ml 100mer MUC1 peptide comprising five 20 amino-acid long tandem repeats from the MUC1 extracellular domain. Similarly diluted sera from two mice with MUC1 negative (wild type) tumors, as well as dilution medium alone were chosen as negative controls. Samples were run in duplicate for each of the two dilutions (1:20 and 1:40, respectively). Horseradish peroxidase (HRP) –conjugated secondary antibody specific for mouse IgG (Sigma, 1:500) was used for detection. Median and standard errors were plotted in Excel.

Survival curve and statistical analysis
The Kaplan-Meyer survival curve was plotted using the GraphPad Prism 6 software. The same software, as well as Excel were used to perform ANOVA or Student’s t test and to compute p values for statistical significance.

Results
Induction of oncogenic Kras\textsuperscript{G12D} and deletion of Pten in the oviduct or the uterine horns triggers progression to ductal and endometrial tumors, respectively

To explore the tumorigenic contributions of oncogenic Kras and tumor suppressor Pten pathways throughout the female genital tract of genetically engineered, Cre-loxP mice [21,26], we injected AdCre adenovirus at three different anatomical locations (Fig. 1A). The mice received one, unilateral AdCre injection either in the ovarian bursa (n = 12), oviduct (the fallopian tube equivalent, n = 9) or uterine horn (n = 12). Activation of Kras and deletion of Pten transformed the oviductal and endometrial tissues, resulting in establishment of primary tumors at these sites (Fig. 1B). Oviductal tumors showed 100% tumor penetrance (n = 9), similarly to ovarian tumors [21,26]. Tumor penetrance was lower (at 50%) following intrauterine (IU) AdCre injections. Intrabursal injections triggered primary ovarian tumors as shown previously [21,26] and were used as reference standard (Fig. 1B).

Gross loco-regional metastases were often observed in late stage tumors of oviduct and uterus (Fig. 1B) and were detected as tumor implants on the diaphragm, liver, and spleen. Only one of the 12 uterine-injected mice presented with ascites (8%) while 5 out of 9 oviduct injected mice showed ascites (56%, p = 0.0163). Ascites, when detected, was of the hemorrhagic type. No tumors were detected in the ovaries, oviduct and uterine-AdCre injected mice carrying mutations in either Kras alone (MK mice) or Pten alone (MP mice, data not shown), suggesting that, as with ovarian tumors [26], both pathways need to be active in order for tumors to occur. AdCre was also injected in MUC1 single transgenic mice (included as controls) which, as expected, remained healthy throughout the duration of the experiment. This demonstrates that in the absence of floxed mutations in the host genome, adenoviral infection is non-consequential for the host.

DNA of all primary tumors was analyzed by PCR to confirm the activation of the floxed sites in Kras and Pten genes [26]. As expected, the oviducal and uterine tumors showed the presence of both the active Kras\textsuperscript{G12D} and the wild type Kras alleles, along with homozygous deletion of Pten (Fig. S1A–C). Normalization results of mutant (floxed) Kras to wild type Kras from tumors are in line with the expected 1:1 ratio (50% mutant Kras), although the oviduct and endometrial show slightly lower and higher ratios, respectively (Fig. S1D). A similar efficiency of recombination was observed for floxed Pten that could be detected in these lesions (Fig. S1E). In contrast, no wild type was detected, consistent with the fact that macro-dissected tissue consisted mostly of epithelium. However, a weak band for wild type Pten could be detected in the ex vivo isolated ovarian tumor cell line using freshly isolated DNA,
also suggesting the negative result can in part be due to a limitation in detecting residual Pten by PCR when using paraffin-extracted DNA (Fig. S1F). Through reporter gene (AdLacZ) experiments, we further confirmed that injections remain anatomically confined and effectively trigger local epithelial infection of uterus, oviduct and ovaries (Fig. S2).

Oviductal and uterine tumors are of epithelial origin and show endometrioid histology

Both oviductal and uterine tumor cells were positive for cytokeratin 8, an epithelial marker, and negative for desmin, a stromal cell marker (Fig. 2), confirming the epithelial origin of these tumors. Similarly to KrasPten- induced ovarian tumors obtained via AdCre injections under the ovarian bursa [21], both the oviductal and uterine primary tumors displayed endometrioid histology (Fig. 3). The endometrioid histology was also preserved in loco-regionally spread tumor implants (Fig. 3). Our findings demonstrate that, in this preclinical model, co-involvement of Kras and Pten tumorigenic pathways throughout the genital tract (ovaries, oviduct and uterus) consistently triggers gynecologic tumors with endometrioid histology. Notably however, some of the uterine lesions in mice sacrificed early, potentially before tumor onset, showed glandular hyperplasia with cystic dilation (Fig. S3).

KrasPten-driven oviductal and uterine tumors express human MUC1 and trigger spontaneous anti-MUC1 antibodies

We have previously shown that triple transgenic MUC1KrasP- ten mice, injected with AdCre under the ovarian bursa, develop human MUC1-expressing ovarian tumors, closely mirroring the human disease [21,26]. In this study, we examined whether the oviductal and uterine tumors also expressed MUC1 upon Kras activation and Pten deletion in MUC1KrasPten mice. Our IHC results demonstrate that the tumors lost polarized MUC1 expression normally seen on healthy epithelia (Fig. S4), and show abundant cell surface and cytosolic MUC1 (Fig. 4), similar to the staining pattern observed in human tumors (Fig. S5 and references [30,31]).

In patients, MUC1 overexpression on developing adenocarcinomas leads to spontaneous humoral responses to various MUC1 epitopes from its extracellular domain [32,33]. We asked here whether the gynecologic tumors in MUC1KrasPten mice that express MUC1 antigen as self also trigger MUC1-specific humoral immunity. ELISA measurements show that although the amplitude of the response varies, presence of MUC1-specific IgG antibodies can be detected in serum of tumor bearing mice (Fig. 4B) and the levels are significantly higher in mice with ovarian and oviduct tumors. Since the target peptide is a 100mer MUC1 peptide comprising five tandem repeats from the...
extracellular portion of MUC1, these responses are indicative of humoral immunity against underglycosylated, tumor-like MUC1, as previously shown by us and others [26]. Furthermore, mice with endometrial hyperplasia also have detectable levels of MUC1-specific antibodies, suggesting that MUC1 humoral immunogenicity is an early event, triggered by early precursors (Fig. S3D).

Overall, these results demonstrate that MUC1KrasPten mice represent the first immune competent, orthotopic, human MUC1-expressing preclinical tumor model for epithelial cell-derived oviduct and endometrial tumors. The tumors have well defined (endometrioid) histology, and, as with ovarian tumors [26], overexpress MUC1 and trigger detectable levels of spontaneous MUC1-specific humoral responses, closely mirroring the immunogenicity seen in the respective human diseases [32,33].

KrasPten- induced oviductal and uterine tumors differ in their nuclear grade, survival and immune microenvironment

Although all genital tract tumors were endometrioid, a detailed analysis of the H&E histo-pathology revealed that only oviduct tumors developed as poorly differentiated, high nuclear grade tumors, in contrast to the uterine and ovarian tumors which occurred primarily as low/intermediate grade tumors (Fig. 5A). Furthermore, mice with oviduct tumors had the lowest median survival (12 weeks), significantly shorter than mice with endometrial tumors (Fig. 5B, p = 0.001). Surprisingly, no significance was reached when compared with mice bearing ovarian tumors (13 weeks median survival, Table S1). Thus, the ovarian and oviductal tumors mirror the characteristics of the human ovarian [1] and fallopian tube cancers and share a similarly low survival, in spite of the high nuclear grade observed only in the latter.
To explore the relationship between survival, the observed phenotype of oviduct tumors and the immune status of the host, we phenotyped the splenic T cells via multicolor flow cytometry and analyzed the percentages of all CD8 and CD4 T lymphocytes, and of Foxp3+ (Treg) subset. The ratio of suppressors (Tregs) to effectors (CD8 T lymphocytes) has been shown to correlate inversely with survival of patients with ovarian [34] or other types of tumors [35–37]. In line with these reports, we observed an increased Foxp3+ T cell accumulation in the spleen of oviduct tumor- bearing mice and a higher ratio of Treg/CD8 in these mice compared to mice with uterine tumors (n = 5 mice/group), represented as box and whisker diagrams (min, Q1, median, Q3, max). CD4 and CD8 T lymphocytes were gated under the CD3 population. Foxp3 cells were gated under the CD4 population. One way ANOVA for comparison of all means (p<0.03) and two tail t tests between any two groups show significant differences between the ratios in uterine tumors and any of the other two tumor types, ovarian and oviduct (p<0.02 and p<0.01, respectively).

doi:10.1371/journal.pone.0102409.g005

To explore the relationship between survival, the observed phenotype of oviduct tumors and the immune status of the host, we phenotyped the splenic T cells via multicolor flow cytometry and analyzed the percentages of all CD8 and CD4 T lymphocytes, and of Foxp3 + (Treg) subset. The ratio of suppressors (Tregs) to effectors (CD8 T lymphocytes) has been shown to correlate inversely with survival of patients with ovarian [34] or other types of tumors [35–37]. In line with these reports, we observed an increased Foxp3 + T cell accumulation in the spleen of oviduct tumor- bearing mice and a higher ratio of Treg/CD8 in these mice compared to mice with uterine tumors (Fig. 5C, p<0.01). No differences were noted between mice with ovarian and oviduct tumors, suggesting that both anatomical locations are similar in inducing an immune suppressive phenotype in the host, despite the high nuclear grade observed only in the latter.

Discussion

Studies on targeted therapies, including immune-based approaches, require the development of adequate preclinical models that best reflect the pathogenic changes seen in the human disease. In this study, we generated two novel human MUC1- expressing mouse models of oviductal and endometrial cancers respectively, based on simultaneous KrasG12D activation and Pten deletion mutations [21,26]. Using triple transgenic MUC1KrasPten mice [26] we show for the first time that concomitant activation of oncogenic Kras and deletion of Pten tumor suppressor throughout the female mouse genital tract consistently triggers MUC1 positive epithelial tumors with endometrioid histology. We previously showed that MUC1 distribution throughout the genital tract of MUC1KrasPten healthy mice is similar to the one seen in women [26]. Here, we demonstrate that progression to genital cancers triggers loss of polarized distribution and significant increase in
MUC1 protein expression. Furthermore, these changes trigger humoral immune responses, most likely due to the release of MUC1 from tumor cell surface followed by expansion of MUC1-specific B cells in tumor draining lymph nodes [32,33,30]. Patients with premalignant and malignant conditions of the genital tract (mostly uterus and ovaries), as well as those affected with other cancers [39] have increased MUC1 antibody titers, although the intensity of these responses is variable. In line with these findings, the transgenic MUC1KrasPten mice employed here, which express human MUC1 as self, are able to undergo similar pathogenic changes leading to local (ascites) and systemic (serum) IgG antibody responses in ovarian, tubal and endometrial tumors. This demonstrates the versatility of MUC1KrasPten mice in modeling, with high fidelity, immunobiology of MUC1 in gynecologic cancers.

A second major finding of our studies stems from the fact that although the same genetic changes were turned on, at a similar rate, throughout the genital tract epithelium (in the ovaries, oviduct, endometrium), the tumor microenvironment seems to be a key determinant of tumor grade and survival. Though contiguous with the uterus and the ovary, and triggered via the same Kras$^{G12D}$ and Pten$^{fl}$ mutations, the oviductal tumors show a higher nuclear grade than those arising in the other organs. In women, the high grade serous ovarian tumors are believed to arise from fallopian tubes [4,5,15,40]. This hypothesis is further validated by recent preclinical studies from Perets et al. who reported a genetic model of de novo high grade serous carcinoma that originates in the fallopian tube epithelium and recapitulates the biology of human invasive ovarian cancer [23]. Our results raise the previously unexplored possibility that fallopian tubes may also play a causative role in (albeit rare) cases of high grade endometrioid or mixed endometrioid-serous ovarian carcinomas. There are several examples in human carcinogenesis where the anatomical site of initiating lesions dictates the cancer risk, including the cervical epithelial transformation zone with HPV [41], the esophageal-gastric junction and Barrett’s esophagus [42], and the squamous cell metaplasia in lung cancer [43]. Here we report that the intrinsic nature of the mucosal-epithelial biology of the fallopian tube may promote a more aggressive phenotype, as compared to the adjacent uterine mucosa when exposed to the same carcinogenic influence. Our approach opens the door for future studies focused on the identification of fallopian tube-specific molecular pathways engaged in tumorigenesis and development of new therapies that target these pathways. It also provides further support to the rationale of scrutinizing the fallopian tubes when searching for premalignant or early precursors to high grade ovarian tumors, regardless of their histology.

Preclinical mouse models to study oviductal cancer, the murine equivalent of human fallopian tube carcinoma, are difficult to develop. Recent studies from Kim et al utilized the anti-müllerian hormone receptor 2 (Amhr2) gene locus to deliver the Cre recombinase and conditionally delete the Dicer and the Pten genes in the Müllerian ducts to establish ductal cancer closely resembling the human disease [15]. However, the Amhr2 gene is expressed not only in oviductal cells but also in the uterine epithelium as well as the ovarian granulosa cells [19], making this model non-exclusive for primary oviductal tumors. Similarly, we acknowledge the technical challenges posed by induction of oviduct tumors in our MUC1KrasPten mice. Oviducts are minute tubes that provide a space continuum between the uterine horns and the ovarian bursa. To diminish the risk of leakiness, and to ensure that AdCre injections remain anatomically confined to the oviducts, we clipped the proximal and distal ends of the tubes, prior to AdCre injections. The contrasting histomorphology (high grade in oviducts versus low grade in ovaries and uterus) suggests that the originating cells were indeed from the oviduct and that tumors were not merely spreading from the contiguous genital tract areas (ovary and uterus, respectively).

Unlike oviduct tumors, several preclinical models of uterine carcinomatosis are currently available. Conditional deletions of tumor suppressors such as Pten and p53 in the endometrium trigger invasive endometrial adenocarcinomas [17,18]. In line with these studies, our endometrial cancer mouse model did not show 100% penetrance. Mice with no visible tumors showed signs of endometrial hyperplasia. The lesions were immunogenic and triggered MUC1 antibodies, making this model attractive for studies on MUC1 in uterine premalignancy.

The tumor microenvironment, composed of stroma and immune cells, has recently received emphasis as a target in treatment of ovarian cancer [44]. Our study reinforces its role in the development of gynecological cancers. In addition, oviduct tumor-bearing mice have Treg to CD8 ratios that are higher than in mice with uterine tumors, yet not significantly different from mice with ovarian tumors. This suggests that the oviducts promote a more immune suppressive environment, perhaps similarly to ovaries, via CXCL12 [45], although the exact mechanisms remain to be identified.

Taken together, our studies establish two new, highly versatile human MUC1- expressing mouse models of Kras- and Pten-induced oviductal and endometrial cancers with endometrioid histology, which closely mirror the pathology and immunogenicity of human disease, and demonstrate the influence of the tumor microenvironment on gynecological cancer development.

**Supporting Information**

**Figure S1** Cre-mediated recombination at Kras and Pten loci, in tumor-extracted DNA. PCR analysis of tumor-extracted DNA shows concomitant activation of oncogenic KrasG12D mutation (A) and deletion of Pten (B). Non-deleted Pten is shown in (C). DNA from a healthy transgenic mouse was used as negative controls in and B and positive control in C. DNA from an ovarian cancer cell line was used as positive control in A and B. (A) Floxed out, activated Kras shows up as upper band. (B) Floxed out Pten shows as a single band; no band demonstrates absence of Cre-loxP recombination. (C) Wild type Pten allele (arrow). (D) Activated Kras levels expressed as percentage of total K-Ras in each sample. (E, F) Pten deletion and wild type Pten allele, respectively; y axis, signal intensity (arbitrary units). Signal in D-F were quantified using Image Studio Lite (LI-COR). Ov T; ovarian tumor; Od T; oviduct tumor; Endom; endometrial tumor. (TIF)

**Figure S2** AdLacZ administration into the oviduct or the uterus was performed followed by staining for β-galactosidase expression. 4 micron sections of the specific tissue were cut and HE stained to reveal the tissue histology. β-galactosidase expression in epithelia of oviduct and the endometrium indicate successful delivery of the adenovirus. A representative section is shown for each oviduct and uterine anatomical site (Scale bars: low magnification ~100 µm, high magnification ~50 µm. (TIF)

**Figure S3** (A) Baseline endometrial histology of a healthy mouse. (HE stain) (B) Premalignant lesions display cystic dilation and endometrioid hyperplasia. (HE stain) (C) The cyst lining as well as the hyperplastic endometrial glands express human MUC1 (IHC for MUC1 using anti-human MUC1 antibody, clone HMPV).
Scale bar = 200 μm. (D) Dot plot of IG10-MUC1 cells incubated with serum from uterine injected female mouse with endometrial hyperplasia. Gated population represents percent tumor cells stained by MUC1-specific antibodies present in the serum.

**Figure S4** Histomorphology and MUC1 expression in the normal mouse female genital tract. Left column: HE stain of a female genital tract of a healthy, MKP mouse showing normal, baseline histology of the ovary, oviduct and uterus. Right column: IHC stain for human MUC1 expression in the ovary, oviduct and uterus of a healthy MKP female mouse. Scale bar = 50 μm.

**Figure S5** Histomorphology and MUC1 expression in human gynecologic tumors. Left column: HE stain of human fallopian tube carcinoma, endometrial carcinoma and endometrial hyperplasia. Right column: IHC stain for human MUC1 expression. Representative images shown. Scale bar = 50 μm.

**Table S1** Median survival and number of mice in each tumor group.

**Acknowledgments** We would like to thank Dr. Kristin Zorn for technical advice on oviduct clippings.

**Author Contributions** Conceived and designed the experiments: AMV TST RAB. Performed the experiments: TST RAB EE JTM LZ AMV. Analyzed the data: AMV TST RAB EE LZ JB. Contributed reagents/materials/analysis tools: AMV EE RPE. Wrote the paper: AMV TST RAB RPE EE.


